LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint. Results were shared as one of two LEO Pharma late breaker oral presentations at the 2023 American Academy of Dermatology (AAD) Annual Meeting.1 LEO 138559 is an investigational agent and its efficacy and safety are subject to further larger trials.
LEO 138559 is an investigational monoclonal antibody currently in Phase 2 development for the treatment of moderate-to-severe atopic dermatitis, which blocks the IL-22RA1 receptor subunit thereby inhibiting the effect of the interleukin-22 (IL-22) cytokine – known to be elevated in patients with atopic dermatitis.1–3 LEO 138559 potentially also inhibits to some extent the effects of cytokines IL-20 and IL-24; however, this remains to be fully understood.1
“We know that atopic dermatitis is a complex immunological condition and LEO Pharma is committed to supporting patients and clinicians in dermatology by finding new ways to treat this chronic disease,” said Jörg Möller, Executive Vice President, Global Research and Development, LEO Pharma. “We are encouraged by these Phase 2a results, in moderate-to-severe atopic dermatitis and plans are underway for a Phase 2b trial.”
The results from the Phase 2a trial in 58 adult patients showed that LEO 138559 dosed at 450 mg every other week (Q2W) via subcutaneous injections for 16 weeks had a favourable safety profile.1 LEO 138559 demonstrated significant improvement compared with placebo in the primary endpoint of change in EASI score from baseline (-15.3 vs. -3.5) and across a range of endpoints including EASI-75 (41.6% vs.13.7%), EASI-90 (30.8% vs. 3.5%), EASI-100 (20.9% vs. 0%) and vIGA-AD 0/1 (27.3% vs. 7.0%).1 The most frequently reported AEs in the LEO 138559 versus placebo arms were COVID-19 (13.8% vs 6.9%), dermatitis atopic (13.8% vs 13.8%), and upper respiratory tract infection (3.4% vs 10.3%).1
“These results are promising, as they demonstrate for the first time the potential benefits of targeting the IL-22 receptor which is a new mode of action”, said Professor Diamant Thaci, MD, Head of Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany and the international coordinating investigator for the Phase 2a trial. “Patients with moderate-to-severe atopic dermatitis still face numerous unmet needs and we welcome any new advances that could provide us with additional options to help them.”
LEO Pharma and argenx BV formed a strategic alliance in 2015 to develop innovative antibody-based solutions for the treatment of chronic inflammation that underlies many skin conditions. LEO Pharma and argenx BV jointly developed LEO 138559 under an exclusive option and research agreement. LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.
The collaboration between LEO Pharma and argenx BV stands as a strong example of an external innovation sourcing model, which is a key pillar in LEO Pharma’s new Research and Development strategy.
About the Phase 2a trial
The LEO 138559 Phase 2a trial (NCT04922021) was a randomized, double-blind, placebo-controlled, multi-site, trial to evaluate the efficacy and safety of LEO 138559 in adult patients with moderate-to-severe atopic dermatitis. Patients were randomized 1:1 (n=29 per arm) to receive either LEO 138559 dosed at 450 mg Q2W or placebo, for 16 weeks. The primary endpoint was change in EASI score from baseline to Week 16.1 Other endpoints included EASI-75, EASI-90, EASI-100 (which represent a 75, 90 and 100 percent improvement in atopic dermatitis area and severity) and vIGA-AD 0/1 (proportion of patients who achieved ‘clear’ or ‘almost clear’ skin).1
About atopic dermatitis
Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.4 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.5
About investigational LEO 138559
LEO 138559 is an investigational monoclonal antibody that targets the IL-22RA1 receptor subunit, currently in Phase 2 development for the potential treatment of moderate-to-severe atopic dermatitis.1 It blocks the IL-22RA1 subunit and thereby inhibits the effects of the IL-22 cytokine, and potentially also to some extent the effects of IL-20 and IL-24.1 LEO 138559 does not bind to the IL-22 cytokine itself.1 LEO Pharma has obtained a worldwide exclusive license to develop and commercialize LEO 138559 from argenx BV.
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion. Learn more at www.leo-pharma.com.
About argenx BV
argenx BV is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. For more information, visit www.argenx.com
- Thaci D, et al. Presented at American Academy of Dermatology (AAD) 2023 Annual Meeting, New Orleans, March 17–21 2023.
- Fujita H. J Dermatol Sci 2013;72:3–8.
- Czarnowicki T, et al. J Allergy Clin Immunol 2019;143:1–11.
- Weidinger S, et al. Lancet 2016;387:1109–1122.
- Boguniewicz M, et al. Immunol Rev 2011;242:233–246
MAT-64076 March 2023
View source version on businesswire.com: https://www.businesswire.com/news/home/20230318005014/en/